Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Impact of Fluorescence-Guided Resection and Chemoradiotherapy on the Systemic Immune Response in Glioblastoma: A Kinetic Analysis of Immune Biomarkers.

NCT07568782 is registered in ClinicalTrials.gov with University Hospital, Lille as lead sponsor.

NCT NCT07568782
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT07568782 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Impact of Fluorescence-Guided Resection and Chemoradiotherapy on the Systemic Immune Response in Glioblastoma: A Kinetic Analysis of Immune Biomarkers.
Lead sponsor
University Hospital, Lille
Phase
Observational
Overall status
Not yet recruiting
Start date
October 15, 2026
Completion date
October 15, 2028
Enrollment
17 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

glioblastoma